You are here

Akers Biosciences Further Extends Outsourced US Distribution Capabilities for Heparin PF4 Rapid Test

THOROFARE, N.J., July 03, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, announces agreements with six more Independent Sales Representative (ISR) organizations to further expand US sales and marketing capabilities for the Company’s rapid test for heparin-induced thrombocytopenia (HIT).

The agreements are with Stone Mountain Surgical, Aspen Scientific, Evolution Surgical, ACT Medical, BCD Medical and Tuzik Boston. Each of the newly appointed ISRs sells and/or distributes medical devices, including surgical instruments and supply products used in cardio vascular, cardio thoracic and general surgery.

Each organization has key relationships with surgeons across their footprints. This aligns with Akers Bio’s strategy to increase platelet factor 4 awareness among clinical end-users and those able to prescribe HIT tests - namely surgeons and surgical teams - and to expand the utilization of the Company’s point-of-care PIFA Heparin/PF4 Rapid Assay product platform.

The Company’s ISR coverage now extends to 27 states across the US, thereby raising awareness on a broad scale and helping to drive sales.

Stone Mountain is a surgical products distributor, focused solely on the healthcare space and has a team covering the states of Washington, Oregon, Colorado, Arizona, New Mexico, Idaho, Wyoming, Montana, Alaska, Hawaii and Utah.

Aspen Scientific is based in the Dallas-Fort Worth Metroplex in Texas and focuses on the distribution of medical devices that are for use in operating rooms in the state of Texas.

Evolution Surgical, based in Houston, Texas, has an 8-year track record serving the healthcare community as a distributor of specialized surgical products. Evolution Surgical has been appointed for its significant relationships with cardiac surgeons and expertise in the distribution of medical devices and equipment. Evolution Surgical will be responsible for distribution in Houston, Texas and surrounding areas.  

ACT Medical has over 30 years’ experience in surgical sales and will focus on the state of Virginia.

BCD Medical has been in operation since 1985 and its sales team will be targeting hospitals and surgeons across the state of Maryland as well as Washington, D.C.

Tuzik Boston is a specialty surgical products distributor which has been in business since 1922 and will leverage its network and relationships across the states of New England - Maine, New Hampshire, Vermont, Massachusetts, Rhode Island and Connecticut.

In order to fully support all of its ISRs, the Company has produced a training video for end customers. In April 2018, Akers Bio also hosted a webinar entitled Anti-Heparin Platelet Factor 4 Antibodies: Risking a Potentially Catastrophic Occurrence. The webinar, which seeks to raise awareness among healthcare professionals, has already been viewed by over 300 healthcare professionals and can be viewed here.

John J. Gormally, Chief Executive Officer of Akers Bio, commented: “We are delighted to have further enhanced our Independent Sales Representative network across the US. The capabilities of all our appointed ISRs are intentionally focused on surgeons and surgical teams. At the core of our strategy is to influence the clinical pathway for the diagnosis of HIT and therefore drive sales of PIFA Heparin/PF4 Rapid Assay products. With a rapidly expanding footprint across the US, we are able to raise awareness of the benefits of our tests across the key clinical end-user audiences on a broad scale.”

About Akers Biosciences, Inc.

Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found at Follow us on Twitter @AkersBio.

Cautionary Note Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, compliance with the requirements of various regulatory agencies, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions, as they relate to the Company, its subsidiaries, or its management. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results, performance, prospects, and opportunities to may differ materially from those set forth in, or implied by, the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

CONTACT: For more information:

Akers Biosciences, Inc.
John J. Gormally, Chief Executive Officer
Tel. +1 856 848 8698

Vigo Communications (Global Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7390 0234
Tuesday, July 3, 2018 - 07:00